Cargando…

Hemodynamic monitoring in cardiogenic shock

Cardiogenic shock (CS) is a life-threatening condition characterized by acute end-organ hypoperfusion due to inadequate cardiac output that can result in multiorgan failure, which may lead to death. The diminished cardiac output in CS leads to systemic hypoperfusion and maladaptive cycles of ischemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamzaoui, Olfa, Boissier, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175734/
https://www.ncbi.nlm.nih.gov/pubmed/37188114
http://dx.doi.org/10.1016/j.jointm.2022.10.003
_version_ 1785040274966183936
author Hamzaoui, Olfa
Boissier, Florence
author_facet Hamzaoui, Olfa
Boissier, Florence
author_sort Hamzaoui, Olfa
collection PubMed
description Cardiogenic shock (CS) is a life-threatening condition characterized by acute end-organ hypoperfusion due to inadequate cardiac output that can result in multiorgan failure, which may lead to death. The diminished cardiac output in CS leads to systemic hypoperfusion and maladaptive cycles of ischemia, inflammation, vasoconstriction, and volume overload. Obviously, the optimal management of CS needs to be readjusted in view of the predominant dysfunction, which may be guided by hemodynamic monitoring. Hemodynamic monitoring enables (1) characterization of the type of cardiac dysfunction and the degree of its severity, (2) very early detection of associated vasoplegia, (3) detection and monitoring of organ dysfunction and tissue oxygenation, and (4) guidance of the introduction and optimization of inotropes and vasopressors as well as the timing of mechanical support. It is now well documented that early recognition, classification, and precise phenotyping via early hemodynamic monitoring (e.g., echocardiography, invasive arterial pressure, and the evaluation of organ dysfunction and parameters derived from central venous catheterization) improve patient outcomes. In more severe disease, advanced hemodynamic monitoring with pulmonary artery catheterization and the use of transpulmonary thermodilution devices is useful to facilitate the right timing of the indication, weaning from mechanical cardiac support, and guidance on inotropic treatments, thus helping to reduce mortality. In this review, we detail the different parameters relevant to each monitoring approach and the way they can be used to support optimal management of these patients.
format Online
Article
Text
id pubmed-10175734
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101757342023-05-13 Hemodynamic monitoring in cardiogenic shock Hamzaoui, Olfa Boissier, Florence J Intensive Med Review Cardiogenic shock (CS) is a life-threatening condition characterized by acute end-organ hypoperfusion due to inadequate cardiac output that can result in multiorgan failure, which may lead to death. The diminished cardiac output in CS leads to systemic hypoperfusion and maladaptive cycles of ischemia, inflammation, vasoconstriction, and volume overload. Obviously, the optimal management of CS needs to be readjusted in view of the predominant dysfunction, which may be guided by hemodynamic monitoring. Hemodynamic monitoring enables (1) characterization of the type of cardiac dysfunction and the degree of its severity, (2) very early detection of associated vasoplegia, (3) detection and monitoring of organ dysfunction and tissue oxygenation, and (4) guidance of the introduction and optimization of inotropes and vasopressors as well as the timing of mechanical support. It is now well documented that early recognition, classification, and precise phenotyping via early hemodynamic monitoring (e.g., echocardiography, invasive arterial pressure, and the evaluation of organ dysfunction and parameters derived from central venous catheterization) improve patient outcomes. In more severe disease, advanced hemodynamic monitoring with pulmonary artery catheterization and the use of transpulmonary thermodilution devices is useful to facilitate the right timing of the indication, weaning from mechanical cardiac support, and guidance on inotropic treatments, thus helping to reduce mortality. In this review, we detail the different parameters relevant to each monitoring approach and the way they can be used to support optimal management of these patients. Elsevier 2022-12-05 /pmc/articles/PMC10175734/ /pubmed/37188114 http://dx.doi.org/10.1016/j.jointm.2022.10.003 Text en © 2023 The Authors. Published by Elsevier B.V. on behalf of Chinese Medical Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Hamzaoui, Olfa
Boissier, Florence
Hemodynamic monitoring in cardiogenic shock
title Hemodynamic monitoring in cardiogenic shock
title_full Hemodynamic monitoring in cardiogenic shock
title_fullStr Hemodynamic monitoring in cardiogenic shock
title_full_unstemmed Hemodynamic monitoring in cardiogenic shock
title_short Hemodynamic monitoring in cardiogenic shock
title_sort hemodynamic monitoring in cardiogenic shock
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175734/
https://www.ncbi.nlm.nih.gov/pubmed/37188114
http://dx.doi.org/10.1016/j.jointm.2022.10.003
work_keys_str_mv AT hamzaouiolfa hemodynamicmonitoringincardiogenicshock
AT boissierflorence hemodynamicmonitoringincardiogenicshock